Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 3, 2008, Pages 191-198

  Nakagawa, Yasunori ^a   Ichii, Yoko ^a   Saeki, Yasuhiro ^a   Kodama, Masanobu ^a   Kishino, Satoshi ^b   Suzuki, Kenshi ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Febrile neutropenia; Fungal infection; Micafungin; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISPOSITION; DRUG SAFETY; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; MALE;

EID: 56249110616     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191118     Document Type: Article

References (18)

1. Cornely O.A., Ullmann A.J., Karthaus M. (2003): Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood, 101, 3365-3372.
2. Kohno S., Yamaguchi H. (2002): Overview of micafungin (MCFG). Jap. J. Chemother., 50(S-1), 1-7.
3. Ikeda F., Otomo K., Nakai T., Morishita Y., Maki K., Tawara S., Mutoh, S., Matsumoto, F., Kuwahara, S. (2002): In vitro activity of a new lipopeptide antifungal agent, micafungin against a variety of clinically important fungi. Jap. J. Chemother., 50(S-1), 8-19.
4. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W., Satoi Y., Lee J.M., Walsh T.J.; National Institute of Allergy and Infectious Diseases Mycoses Study Group. (2004): Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis., 39, 1407-1416.
5. Ishikawa T., Takata T., Tomoyose T., Masuda M., Nakachi S., Koga S., Tsukada J., Matsuura A., Utsunomiya A., Saburi Y., Tamura K. (2006): The efficacy of micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents. Jap. J. Chemother., 54, 125-128.
6. Yanada M., Kiyoi H., Murata M., Suzuki M., Iwai M., Yokozawa T., Baba H., Emi N., Naoe T. (2006): Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern. Med., 45, 259-264.
7. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., Niki Y., Ikemoto H. (2004): A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis., 36, 372-379.
8. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K.M., Vazquez J., Anaissie E.J., Lipton J., Jacobs P., Jansen van Rensburg J.H., Rex J.H., Lau W., Facklam D., Buell D.N. (2005): International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis., 24, 654-661.
9. Ruhnke M., Kuse E., Chetchotisakd P., da Cunha C.A., Diekmann-Berndt H. (2005): Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. Program, 228 Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. (Abstract. No.M-722c).
10. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., Sekhon J.S., Freire A., Ramasubramanian V., Demeyer I., Nucci M., Leelarasamee A., Jacobs F., Decruyenaere J., Pittet D., Ullmann A.J., Ostrosky-Zeichner L., Lortholary O., Koblinger S., Diekmann-Berndt H., Cornely O.A. (2007): Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, 369(9572), 1519-27.
11. Yamato Y., Kaneko H., Tanimoto K., Katashima M., Ishibashi K., Kawamura A., Terakawa M., Kagayama A. (2002): Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jap. J. Chemother., 50(S-1), 68-73.
12. Azuma J., Nakahara K., Kagayama A., Kajiho T., Kawamura A., Suematsu H., Mukai T. (2002): Phase I study of micafungin. Jap. J. Chemother., 50(S-1) 104-147.
13. Azuma J., Nakahara K., Kagayama A., Okuma T., Kawamura A., Mukai T. (2002): Pharmacokinetic study of micafungin. Jap. J. Chemother., 50(S-1), 155-184.
14. Azuma J., Nakahara K., Kagayama A., Fujiwara S., Kawamura A., Mukai T. (2002): Pharmacokinetic study of micafungin in elderly subjects. Jap. J. Chemother., 50(S-1), 148-154.
15. Tabata K., Katashima M., Kawamura A., Tanigawara Y., Sunagawa K. (2006): Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol. Pharm. Bull., 29, 1706-1711.
16. Shimoeda S., Ohta S., Kobayashi H., Saitou H., Kubota A., Yamato S., Shimada K., Sasaki M., Kawano K. (2005): Analysis of the blood level of micafungin involving patients with hematological diseases: New findings regarding combination therapy with tacrolimus. Biol. Pharm. Bull. 28, 477-480.
17. Tabata K., Katashima M., Kawamura A., Kaibara A., Tanigawara Y. (2006): Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infection. Drug Metab. Pharmacokin., 21, 324-331.
18. Yamato Y., Kaneko H., Hashimoto T., Katashima M., Ishibashi K., Kawamura A., Terakawa M., Kagayama A. (2002): Pharmacokinetics of the antifungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells. Jap. J. Chemother., 50(S-1), 74-79.